251 related articles for article (PubMed ID: 24451166)
1. Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.
Tsai WK; Jiann BP
Int J Impot Res; 2014; 26(4):141-5. PubMed ID: 24451166
[TBL] [Abstract][Full Text] [Related]
2. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
Hatzimouratidis K; Hatzichristou DG
Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
[TBL] [Abstract][Full Text] [Related]
4. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
5. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
6. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
7. Clinical monograph for drug formulary review: erectile dysfunction agents.
Campbell HE
J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
[TBL] [Abstract][Full Text] [Related]
8. Management of ED under the "severe distress" criteria in the NHS: a real-life study.
Mohee A; Bretsztajn L; Storey A; Eardley I
J Sex Med; 2014 Apr; 11(4):1056-1062. PubMed ID: 24382018
[TBL] [Abstract][Full Text] [Related]
9. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
10. Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
Fusco F; Sicuteri R; Rossi A; Kontodimas S; Haro JM; Imbimbo C; Mirone V;
Asian J Androl; 2009 Sep; 11(5):629-37. PubMed ID: 19701217
[TBL] [Abstract][Full Text] [Related]
11. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.
Nandipati KC; Raina R; Agarwal A; Zippe CD
Drugs Aging; 2006; 23(2):101-17. PubMed ID: 16536634
[TBL] [Abstract][Full Text] [Related]
12. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
13. Failure of PDE5 inhibitor use: a case of nonresponder? (CME).
Chung E
J Sex Med; 2010 Apr; 7(4 Pt 1):1321-3. PubMed ID: 20492423
[No Abstract] [Full Text] [Related]
14. [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
Herlemann A; Gratzke C; Andersson KE; Sievert KD
Urologe A; 2013 Feb; 52(2):204-11. PubMed ID: 23417046
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
[TBL] [Abstract][Full Text] [Related]
16. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy.
Furtado TP; Miranda EP; Deveci S; Jenkins L; Narus J; Nelson C; Mulhall JP
J Sex Med; 2023 Dec; 21(1):29-32. PubMed ID: 37973393
[TBL] [Abstract][Full Text] [Related]
17. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
19. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active.
Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193
[No Abstract] [Full Text] [Related]
20. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
